BRPI0407616A - composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste" - Google Patents

composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste"

Info

Publication number
BRPI0407616A
BRPI0407616A BRPI0407616-8A BRPI0407616A BRPI0407616A BR PI0407616 A BRPI0407616 A BR PI0407616A BR PI0407616 A BRPI0407616 A BR PI0407616A BR PI0407616 A BRPI0407616 A BR PI0407616A
Authority
BR
Brazil
Prior art keywords
compound
heterodimer
mammals
hood
delta
Prior art date
Application number
BRPI0407616-8A
Other languages
English (en)
Inventor
Concepcion Pedregal-Tercero
Miles Goodman Siegel
Russell Dean Stucky
Kumiko Takeuchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0407616A publication Critical patent/BRPI0407616A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO PARA BLOQUEAR UMA COMBINAçãO DE RECEPTOR DE MU, CAPA, DELTA (HETERODìMERO) DESTE EM MAMìFEROS, MéTODO PARA TRATAR OU PREVENIR OBESIDADE E DOENçAS RELACIONADAS, USO DE UM COMPOSTO, E, MéTODO DE SUPRIMIR O APETITE EM UM PACIENTE EM NECESSIDADE DESTE". Um composto da fórmula (I): ou um sal, enantiómero, racemato, diastereómeros farmaceuticamente aceitáveis ou misturas destes ou um solvato destes, formulações e métodos de uso deste, como antagonistas do receptor opióide são divulgados, em que as variáveis são descritas neste.
BRPI0407616-8A 2003-03-07 2004-02-25 composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste" BRPI0407616A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45341403P 2003-03-07 2003-03-07
PCT/US2004/003360 WO2004080968A1 (en) 2003-03-07 2004-02-25 6-substituted nicotinamide derivatives as opioid receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0407616A true BRPI0407616A (pt) 2006-02-14

Family

ID=32990768

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407616-8A BRPI0407616A (pt) 2003-03-07 2004-02-25 composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste"

Country Status (11)

Country Link
US (2) US7399774B2 (pt)
EP (1) EP1613597B1 (pt)
CN (1) CN1756746A (pt)
AT (1) ATE377589T1 (pt)
AU (1) AU2004220112A1 (pt)
BR (1) BRPI0407616A (pt)
CA (1) CA2518194A1 (pt)
DE (1) DE602004009905T2 (pt)
ES (1) ES2294475T3 (pt)
MX (1) MXPA05009508A (pt)
WO (1) WO2004080968A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140236A (en) * 2002-09-19 2009-12-31 Lilly Co Eli Diarylether compounds useful as opioid receptor antagonists
BRPI0407616A (pt) * 2003-03-07 2006-02-14 Lilly Co Eli composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste"
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US7196100B2 (en) 2003-12-12 2007-03-27 Eli Lilly And Company Opioid receptor antagonists
AU2004312312A1 (en) 2003-12-22 2005-07-21 Eli Lilly And Company Opioid receptor antagonists
JP2007528898A (ja) 2004-03-12 2007-10-18 イーライ リリー アンド カンパニー オピオイド受容体拮抗物質
DE602005012380D1 (de) 2004-03-15 2009-03-05 Lilly Co Eli 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit
WO2005092836A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
MX2007006754A (es) * 2004-12-07 2007-07-09 Glaxo Group Ltd Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
KR101372941B1 (ko) * 2006-05-30 2014-03-14 얀센 파마슈티카 엔.브이. 히스타민 ｈ３ 수용체 조절제로서의 치환된 피리딜 아미드 화합물
CN101522614B (zh) * 2006-08-09 2014-06-25 史密丝克莱恩比彻姆公司 作为阿片样物质受体的拮抗剂或反向激动剂的化合物
CA2662766C (en) 2006-09-08 2011-08-09 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
WO2008089310A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
JP2010527980A (ja) * 2007-05-22 2010-08-19 プロシディオン・リミテッド 代謝障害を治療するための二環状アリールおよびヘテロアリール化合物
TWI425945B (zh) * 2007-05-28 2014-02-11 Seldar Pharma Inc 四氫異喹啉－１－酮衍生物或其鹽
JP2010538055A (ja) 2007-09-07 2010-12-09 プロシディオン・リミテッド 二環式アリールおよびヘテロアリール受容体モジュレーター
EA017484B1 (ru) * 2008-01-22 2012-12-28 Эли Лилли Энд Компани Селективный антагонист опиоидных рецепторов каппа
TW200936130A (en) * 2008-02-26 2009-09-01 Lundbeck & Co As H Uses of indane compounds
ES2397764T3 (es) 2008-04-01 2013-03-11 Abbott Gmbh & Co. Kg Tetrahidroisoquinolinas, composiciones farmacéuticas que las contienen, y su uso en terapia
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
CN103547566B (zh) 2011-02-18 2017-05-31 阿萨纳生物科技有限责任公司 氨基茚满化合物及其治疗疼痛的用途
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2014521682A (ja) 2011-08-05 2014-08-28 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノクロマン、アミノチオクロマンおよびアミノ−１，２，３，４−テトラヒドロキノリン誘導体、これらを含有する医薬組成物、ならびに治療におけるこれらの使用
EP2780328A1 (en) 2011-11-18 2014-09-24 Abbvie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
TWI603957B (zh) 2012-08-15 2017-11-01 阿沙納生物科學有限責任公司 胺基氫茚化合物用於治療膀胱過動症及間質性膀胱炎之用途
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2016004936A (es) 2013-10-17 2016-12-20 Abbvie Deutschland Derivados de aminocromano, aminotiocromano y amino-1,2,3,4-tetrahi droquinilina, composiciones farmaceuticas que los contienen, y su uso en terapia.
WO2015055771A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2022169230A1 (ko) * 2021-02-03 2022-08-11 단국대학교 천안캠퍼스 산학협력단 6-메톡시니코틴아미드를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
TW202400135A (zh) 2022-03-07 2024-01-01 美商健生醫藥公司 包含阿替卡普蘭之組成物
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114046A0 (en) * 1994-06-20 1995-10-31 Astra Ab New opioid peptide antagonists
IT1275433B (it) * 1995-05-19 1997-08-07 Smithkline Beecham Farma Derivati di diarildiammine
DE69711519T2 (de) 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazolanaloge als selektive beta3-adrenergische Agonisten
DK1049676T3 (da) 1997-12-24 2006-01-16 Ortho Mcneil Pharm Inc 4-[Aryl(piperidin-4-yl)]aminobenzamider, som binder til delta-opioidreceptoren
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
SI1859798T1 (sl) 2001-03-29 2016-07-29 Eli Lilly And Company N-(2-ariletil) benzil amini kot antagonisti 5-ht6 receptorja
MY140236A (en) 2002-09-19 2009-12-31 Lilly Co Eli Diarylether compounds useful as opioid receptor antagonists
BRPI0407616A (pt) * 2003-03-07 2006-02-14 Lilly Co Eli composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste"

Also Published As

Publication number Publication date
WO2004080968A1 (en) 2004-09-23
DE602004009905T2 (de) 2008-08-28
EP1613597B1 (en) 2007-11-07
ATE377589T1 (de) 2007-11-15
US8101638B2 (en) 2012-01-24
MXPA05009508A (es) 2005-12-14
EP1613597A1 (en) 2006-01-11
US7399774B2 (en) 2008-07-15
CN1756746A (zh) 2006-04-05
US20060205715A1 (en) 2006-09-14
DE602004009905D1 (de) 2007-12-20
CA2518194A1 (en) 2004-09-23
ES2294475T3 (es) 2008-04-01
US20090023785A1 (en) 2009-01-22
AU2004220112A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
BR0314308A (pt) Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
WO2003048164A3 (en) Adenosine a2a receptor antagonists
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
EA200701357A1 (ru) Композиции и способы применения модулятора рецептора 5ht
BRPI0408108A (pt) composto, composição farmacêutica, métodos para bloquear em receptor mu, kappa, delta ou uma combinação de receptores dos mesmos em um mamìfero, para tratar ou prevenir obesidade e doenças relacionadas e para suprimir apetite, e, uso de um composto
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
BRPI0417156A (pt) composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
EP1539234A4 (en) METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
WO2005056524A3 (en) Therapeutic agents useful for treating pain
BR0311931A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
IL179599A0 (en) Glucagon receptor antagonists, preparation and therapeutic uses
BR0306980A (pt) Composto, uso de um composto, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com o receptor de histamina h3
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
WO2005062894A3 (en) Co-administration of dopamine-receptor binding compounds
WO2004026837A3 (en) Histamine h3 receptor antagonists, preparaton and therapeutic uses
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]